1. Home
  2. ARBE vs IMA Comparison

ARBE vs IMA Comparison

Compare ARBE & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arbe Robotics Ltd.

ARBE

Arbe Robotics Ltd.

HOLD

Current Price

$0.32

Market Cap

56.3M

Sector

Technology

ML Signal

HOLD

IMA

ImageneBio Inc.

SELL

Current Price

$3.82

Market Cap

66.3M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
ARBE
IMA
Founded
2015
2019
Country
Israel
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
56.3M
66.3M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
ARBE
IMA
Price
$0.32
$3.82
Analyst Decision
Buy
Buy
Analyst Count
3
4
Target Price
$2.63
★ $18.00
AVG Volume (30 Days)
★ 808.6K
14.3K
Earning Date
11-19-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $800,000.00
Revenue This Year
$301.71
N/A
Revenue Next Year
$427.31
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.35
$3.00
52 Week High
$1.94
$7.60

Technical Indicators

Market Signals
Indicator
ARBE
IMA
Relative Strength Index (RSI) 27.34 47.97
Support Level N/A N/A
Resistance Level $0.91 $4.37
Average True Range (ATR) 0.04 0.33
MACD -0.01 0.03
Stochastic Oscillator 0.53 69.62

Price Performance

Historical Comparison
ARBE
IMA

About ARBE Arbe Robotics Ltd.

Arbe Robotics Ltd is a provider of 4D Imaging Radar solutions enabling driver-assist systems while paving the way for fully autonomous driving. It is a research and development company in the field of chips for Advanced radar systems, which are mainly intended to be used as Advanced Driver Assistance Systems (ADAS) adapted for autonomous vehicles, as well as for non-automotive uses. Geographically, the company generates maximum revenue from Sweden, and the rest from China, Hong Kong, the USA, Germany, Israel, and other markets.

About IMA ImageneBio Inc.

ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.

Share on Social Networks: